Literature DB >> 2573072

Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease.

J A Wolff1, L J Fisher, L Xu, H A Jinnah, P J Langlais, P M Iuvone, K L O'Malley, M B Rosenberg, S Shimohama, T Friedmann.   

Abstract

Rat fibroblasts were infected with a retroviral vector containing the cDNA for rat tyrosine hydroxylase [TH; tyrosine 3-monooxygenase; L-tyrosine, tetrahydropteridine:oxygen oxidoreductase (3-hydroxylating), EC 1.14.16.2]. A TH-positive clone was identified by biochemical assay and immunohistochemical staining. When supplemented in vitro with pterin cofactors required for TH activity, these cells produced L-dopa and released it into the cell culture medium. Uninfected control cells and fibroblasts infected with the TH vector were grafted separately to the caudate of rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. Only grafts containing TH-expressing fibroblasts were found to reduce rotational asymmetry. These results have general implications for the application of gene therapy to human neurological disease and specific implications for Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2573072      PMCID: PMC298422          DOI: 10.1073/pnas.86.22.9011

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Transformation of mammalian cells by avian myelocytomatosis virus and avian erythroblastosis virus.

Authors:  K Quade
Journal:  Virology       Date:  1979-10-30       Impact factor: 3.616

2.  Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells.

Authors:  M Wigler; S Silverstein; L S Lee; A Pellicer; Y c Cheng; R Axel
Journal:  Cell       Date:  1977-05       Impact factor: 41.582

3.  Factors affecting long-term stability of Moloney murine leukemia virus-based vectors.

Authors:  L Xu; J K Yee; J A Wolff; T Friedmann
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

4.  Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter.

Authors:  P J Southern; P Berg
Journal:  J Mol Appl Genet       Date:  1982

5.  Letter: A variant of phenylketonuria.

Authors:  I Smith; B E Clayton; O H Wolff
Journal:  Lancet       Date:  1975-02-08       Impact factor: 79.321

Review 6.  The mechanisms of action of L-dopa in Parkinson's disease.

Authors:  O Hornykiewicz
Journal:  Life Sci       Date:  1974-10-01       Impact factor: 5.037

7.  Intracerebral grafting of neuronal cell suspensions. IV. Behavioural recovery in rats with unilateral 6-OHDA lesions following implantation of nigral cell suspensions in different forebrain sites.

Authors:  S B Dunnett; A Björklund; R H Schmidt; U Stenevi; S D Iversen
Journal:  Acta Physiol Scand Suppl       Date:  1983

8.  Functional activity of substantia nigra grafts reinnervating the striatum: neurotransmitter metabolism and [14C]2-deoxy-D-glucose autoradiography.

Authors:  R H Schmidt; M Ingvar; O Lindvall; U Stenevi; A Björklund
Journal:  J Neurochem       Date:  1982-03       Impact factor: 5.372

9.  Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease.

Authors:  W Lovenberg; R A Levine; D S Robinson; M Ebert; A C Williams; D B Calne
Journal:  Science       Date:  1979-05-11       Impact factor: 47.728

10.  The site of dopamine formation in rat striatum after L-dopa administration.

Authors:  F Hefti; E Melamed; R J Wurtman
Journal:  J Pharmacol Exp Ther       Date:  1981-04       Impact factor: 4.030

View more
  24 in total

1.  Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer.

Authors:  Deniz Kirik; Biljana Georgievska; Corinna Burger; Christian Winkler; Nicholas Muzyczka; Ronald J Mandel; Anders Bjorklund
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

2.  Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts.

Authors:  C Bencsics; S R Wachtel; S Milstien; K Hatakeyama; J B Becker; U J Kang
Journal:  J Neurosci       Date:  1996-07-15       Impact factor: 6.167

3.  Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Authors:  Caryl E Sortwell; William J Bowers; Scott E Counts; Mark R Pitzer; Matthew F Fleming; Susan O McGuire; Kathleen A Maguire-Zeiss; Howard J Federoff; Timothy J Collier
Journal:  Brain Res       Date:  2006-12-28       Impact factor: 3.252

Review 4.  Human nerual stem cells for brain repair.

Authors:  Seung U Kim; Hong J Lee; In H Park; Kon Chu; Soon T Lee; Manho Kim; Jae K Roh; Seung K Kim; Kyu C Wang
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

Review 5.  Gene therapy for Parkinson's disease.

Authors:  P Horellou; J Mallet
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 6.  Engineering Stem Cells for Biomedical Applications.

Authors:  Perry T Yin; Edward Han; Ki-Bum Lee
Journal:  Adv Healthc Mater       Date:  2015-03-13       Impact factor: 9.933

7.  Genetically modified skin fibroblasts persist long after transplantation but gradually inactivate introduced genes.

Authors:  T D Palmer; G J Rosman; W R Osborne; A D Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-15       Impact factor: 11.205

Review 8.  Tyrosine hydroxylase and Parkinson's disease.

Authors:  J Haavik; K Toska
Journal:  Mol Neurobiol       Date:  1998-06       Impact factor: 5.590

Review 9.  Neurogenetic diseases: molecular diagnosis and therapeutic approaches.

Authors:  U Muller; M B Graeber
Journal:  J Mol Med (Berl)       Date:  1996-02       Impact factor: 4.599

10.  Using viral vectors as gene transfer tools (Cell Biology and Toxicology Special Issue: ETCS-UK 1 day meeting on genetic manipulation of cells).

Authors:  Joanna L Howarth; Youn Bok Lee; James B Uney
Journal:  Cell Biol Toxicol       Date:  2009-10-15       Impact factor: 6.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.